Woo Young Yoo
Woo Young Yoo has a total of 8 co-authors. Here are the top co-authors by number of shared publications:
- Ae Shin Cho
R&D Center, IMGT Co., Ltd., 172, Dolma-ro, Bundang-gu, Seongnam-si 13605, Gyeonggi-do, Korea
1 shared publication - Daehyun Kim
Department of Nano Science and Technology, Graduate School of Convergence Science and Technology, Seoul National University, Seoul 08826, Korea
1 shared publication - Hak Jong Lee
Department of Radiology, Seoul National University Bundang Hospital, Seongnam, Korea
1 shared publication - Hyun Ryoung Kim
R&D Center, IMGT Co., Ltd., 172 Dolma-ro, Seongnam 13605, Republic of Korea
1 shared publication - Hyungwon Moon
IMGT Co., Ltd., Seongnam 13605, Korea
1 shared publication - Seung Soo Lee
IMGT Co., Ltd., Seongnam 13605, Korea
1 shared publication
Latest Publications
- Open Access
- 7 September 2020
- Published by MDPI AG in Pharmaceuticals
- Vol. 13 (9) , 235
Combination Therapy with Doxorubicin-Loaded Reduced Albumin Nanoparticles and Focused Ultrasound in Mouse Breast Cancer Xenografts
Because chemotherapeutic drugs are often associated with serious side effects, the central topic in modern drug delivery is maximizing the localization of drugs at the target while minimizing non-specific drug interactions at unwanted regions. To address this issue, biocompatible nanoparticles have been developed to enhance the drug half-life while minimizing the associated toxicity. Nevertheless, relying solely on the enhanced half-life and enhanced permeability and retention (EPR) effects has been ineffective, and designing stimulus-sensitive nanoparticles to introduce the precise control of drug release has been desired. In this paper, we introduce a pH-sensitive, reduced albumin nanoparticle in combination with focused ultrasound treatment. Not only did these nanoparticles have superior therapeutic efficacy and toxicity profiles when compared to the free drugs in xenograft mouse models, but we were also able to show that the albumin nanoparticles reported in this paper were more suitable than other types of non-reduced albumin nanoparticles as vehicles for drug delivery. As such, we believe that the albumin nanoparticles presented in this paper with desirable characteristics including the induction of strong anti-tumor response, precise control, and superior safety profiles hold strong potential for preclinical and clinical anticancer therapy.
- 7 September 2020
- Published by MDPI AG in Pharmaceuticals
- Vol. 13 (9) , 235
Open AccessCombination Therapy with Doxorubicin-Loaded Reduced Albumin Nanoparticles and Focused Ultrasound in Mouse Breast Cancer Xenografts
Because chemotherapeutic drugs are often associated with serious side effects, the central topic in modern drug delivery is maximizing the localization of drugs at the target while minimizing non-specific drug interactions at unwanted regions. To address this issue, biocompatible nanoparticles have been developed to enhance the drug half-life while minimizing the associated toxicity. Nevertheless, relying solely on the enhanced half-life and enhanced permeability and retention (EPR) effects has been ineffective, and designing stimulus-sensitive nanoparticles to introduce the precise control of drug release has been desired. In this paper, we introduce a pH-sensitive, reduced albumin nanoparticle in combination with focused ultrasound treatment. Not only did these nanoparticles have superior therapeutic efficacy and toxicity profiles when compared to the free drugs in xenograft mouse models, but we were also able to show that the albumin nanoparticles reported in this paper were more suitable than other types of non-reduced albumin nanoparticles as vehicles for drug delivery. As such, we believe that the albumin nanoparticles presented in this paper with desirable characteristics including the induction of strong anti-tumor response, precise control, and superior safety profiles hold strong potential for preclinical and clinical anticancer therapy.